Kristen E Jones1, Elissa K Butler2, Tara Barrack3, Charles T Ledonio4, Mary L Forte4, Claudia S Cohn5, David W Polly1. 1. Departments of Orthopaedic Surgery and Neurosurgery, University of Minnesota, Minneapolis, MN. 2. Department of Surgery, University of Washington, Seattle, WA. 3. Summit Orthopedics, Woodbury, MN. 4. Department of Orthopaedic Surgery, University of Minnesota, Minneapolis, MN. 5. Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN.
Abstract
BACKGROUND: Multilevel posterior spine fusion is associated with significant intraoperative blood loss. Tranexamic acid is an antifibrinolytic agent that reduces intraoperative blood loss. The goal of this study was to compare the percent of total blood volume lost during posterior spinal fusion (PSF) with or without tranexamic acid in patients with adolescent idiopathic scoliosis (AIS). METHODS: Thirty-six AIS patients underwent PSF in 2011-2014; the last half (n=18) received intraoperative tranexamic acid. We retrieved relevant demographic, hematologic, intraoperative and outcomes information from medical records. The primary outcome was the percent of total blood volume lost, calculated from estimates of intraoperative blood loss (numerator) and estimated total blood volume per patient (denominator, via Nadler's equations). Unadjusted outcomes were compared using standard statistical tests. RESULTS: Tranexamic acid and no-tranexamic acid groups were similar (all p>0.05) in mean age (16.1 vs. 15.2 years), sex (89% vs. 83% female), body mass index (22.2 vs. 20.2 kg/m2), preoperative hemoglobin (13.9 vs. 13.9 g/dl), mean spinal levels fused (10.5 vs. 9.6), osteotomies (1.6 vs. 0.9) and operative duration (6.1 hours, both). The percent of total blood volume lost (TBVL) was significantly lower in the tranexamic acid-treated vs. no-tranexamic acid group (median 8.23% vs. 14.30%, p = 0.032); percent TBVL per level fused was significantly lower with tranexamic acid than without it (1.1% vs. 1.8%, p=0.048). Estimated blood loss (milliliters) was similar across groups. CONCLUSIONS: Tranexamic acid significantly reduced the percentage of total blood volume lost versus no tranexamic acid in AIS patients who underwent PSF using a standardized blood loss measure.Level of Evidence: 3. Institutional Review Board status: This medical record chart review (minimal risk) study was approved by the University of Minnesota Institutional Review Board.
BACKGROUND: Multilevel posterior spine fusion is associated with significant intraoperative blood loss. Tranexamic acid is an antifibrinolytic agent that reduces intraoperative blood loss. The goal of this study was to compare the percent of total blood volume lost during posterior spinal fusion (PSF) with or without tranexamic acid in patients with adolescent idiopathic scoliosis (AIS). METHODS: Thirty-six AIS patients underwent PSF in 2011-2014; the last half (n=18) received intraoperative tranexamic acid. We retrieved relevant demographic, hematologic, intraoperative and outcomes information from medical records. The primary outcome was the percent of total blood volume lost, calculated from estimates of intraoperative blood loss (numerator) and estimated total blood volume per patient (denominator, via Nadler's equations). Unadjusted outcomes were compared using standard statistical tests. RESULTS: Tranexamic acid and no-tranexamic acid groups were similar (all p>0.05) in mean age (16.1 vs. 15.2 years), sex (89% vs. 83% female), body mass index (22.2 vs. 20.2 kg/m2), preoperative hemoglobin (13.9 vs. 13.9 g/dl), mean spinal levels fused (10.5 vs. 9.6), osteotomies (1.6 vs. 0.9) and operative duration (6.1 hours, both). The percent of total blood volume lost (TBVL) was significantly lower in the tranexamic acid-treated vs. no-tranexamic acid group (median 8.23% vs. 14.30%, p = 0.032); percent TBVL per level fused was significantly lower with tranexamic acid than without it (1.1% vs. 1.8%, p=0.048). Estimated blood loss (milliliters) was similar across groups. CONCLUSIONS: Tranexamic acid significantly reduced the percentage of total blood volume lost versus no tranexamic acid in AIS patients who underwent PSF using a standardized blood loss measure.Level of Evidence: 3. Institutional Review Board status: This medical record chart review (minimal risk) study was approved by the University of Minnesota Institutional Review Board.
Authors: Amit Jain; Paul D Sponseller; Peter O Newton; Suken A Shah; Patrick J Cahill; Dolores B Njoku; Randal R Betz; Amer F Samdani; Tracey P Bastrom; Michelle C Marks Journal: J Bone Joint Surg Am Date: 2015-03-18 Impact factor: 5.284
Authors: Marios G Lykissas; Alvin H Crawford; Gilbert Chan; Lori A Aronson; Mohammed J Al-Sayyad Journal: J Child Orthop Date: 2013-02-28 Impact factor: 1.548
Authors: Richard E Bowen; Steven Gardner; Anthony A Scaduto; Michael Eagan; Jason Beckstead Journal: Spine (Phila Pa 1976) Date: 2010-01-15 Impact factor: 3.468
Authors: Ran Schwarzkopf; Christine Chung; Justin J Park; Michael Walsh; Jeffrey M Spivak; David Steiger Journal: Spine (Phila Pa 1976) Date: 2010-02-01 Impact factor: 3.468